eliglustat   Click here for help

GtoPdb Ligand ID: 7536

Synonyms: GENZ-112638
Approved drug
eliglustat is an approved drug (FDA (2014), EMA (2015))
Compound class: Synthetic organic
Comment: The marketed formulation contains eliglustat tartrate (PubChem CID 52918379).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 12
Topological polar surface area 71.03
Molecular weight 404.27
XLogP 3.66
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCCCCCC(=O)NC(C(c1ccc2c(c1)OCCO2)O)CN1CCCC1
Isomeric SMILES CCCCCCCC(=O)N[C@@H]([C@@H](c1ccc2c(c1)OCCO2)O)CN1CCCC1
InChI InChI=1S/C23H36N2O4/c1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20/h10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26)/t19-,23-/m1/s1
InChI Key FJZZPCZKBUKGGU-AUSIDOKSSA-N
No information available.
Summary of Clinical Use Click here for help
Eliglustat is approved as a treatment for Gaucher disease type I [2-3]. This drug provides a twice daily, oral alternative to hormone replacement therapy.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Sufferers of Gaucher disease are defective in the production of the enzyme β-glucosidase (GBA, P04062), and this leads to the accumulation of its substrate, glucosylceramide. Excessive intracellular levels of this lipid may cause spleen and liver enlargement, anemia, excessive bleeding and bruising and bone disease. Eliglustat is a novel ceramide analogue designed to partially inhibit glucosylceramide synthase, an enzyme which is involved in the production of glucosylceramide.
External links Click here for help